Journal of Advanced Research (Dec 2023)

LncRNA NIPA1-SO confers atherosclerotic protection by suppressing the transmembrane protein NIPA1

  • Min Jiang,
  • Yu Song,
  • Mei-Xia Ren,
  • Run-Chao He,
  • Xian-Hui Dong,
  • Xue-Heng Li,
  • Zhi-Feng Lu,
  • Shu Li,
  • Jia Wu,
  • Yan-Rou Bei,
  • Fei Liu,
  • Yan Long,
  • Shao-Guo Wu,
  • Xue-Hui Liu,
  • Li-Mei Wu,
  • Hong-Ling Yang,
  • David G. McVey,
  • Xiao-Yan Dai,
  • Shu Ye,
  • Yan-Wei Hu

Journal volume & issue
Vol. 54
pp. 29 – 42

Abstract

Read online

Long non-coding RNAs (lncRNAs) are emerging as important players in gene regulation and cardiovascular diseases. However, the roles of lncRNAs in atherosclerosis are poorly understood. In the present study, we found that the levels of NIPA1-SO were decreased while those of NIPA1 were increased in human atherosclerotic plaques. Furthermore, NIPA1-SO negatively regulated NIPA1 expression in human umbilical vein endothelial cells (HUVECs). Mechanistically, NIPA1-SO interacted with the transcription factor FUBP1 and the NIPA1 gene. The effect of NIPA1-SO on NIPA1 protein levels was reversed by the knockdown of FUBP1. NIPA1-SO overexpression increased, whilst NIPA1-SO knockdown decreased BMPR2 levels; these effects were enhanced by the knockdown of NIPA1. The overexpression of NIPA1-SO reduced while NIPA1-SO knockdown increased monocyte adhesion to HUVECs; these effects were diminished by the knockdown of BMPR2. The lentivirus-mediated-overexpression of NIPA1-SO or gene-targeted knockout of NIPA1 in low-density lipoprotein receptor-deficient mice reduced monocyte-endothelium adhesion and atherosclerotic lesion formation. Collectively, these findings revealed a novel anti-atherosclerotic role for the lncRNA NIPA1-SO and highlighted its inhibitory effects on vascular inflammation and intracellular cholesterol accumulation by binding to FUBP1 and consequently repressing NIPA1 expression.

Keywords